
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES185
The ASCOT-LLA post hoc study290 found that the use of atorvastatin in the diabetic population was not associated with any excess risk of adverse reactions, and there were no significant differences in liver enzyme abnormalities between those allocated statin and placebo. No cases of rhabdomyolysis were reported. Level 1+

[@Poulter_2005]

